Healthcare • Drug Manufacturers - Specialty & Generic
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if XERS is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
28 top institutions tracked
Last 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoverySentiment: bearish
Last trade: sell 12 days ago
Red flags: 2
242 filers reported a long position in XERS for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| BlackRock, Inc. | $115M | 14.5M | +12.2% |
| D. E. Shaw & Co., Inc. | $61.8M | 7.8M | +0.2% |
| VANGUARD CAPITAL MANAGEMENT LLC | $58.1M | 7.3M | +5.1% |
| STATE STREET CORP | $38.2M | 4.8M | +3.5% |
| GEODE CAPITAL MANAGEMENT, LLC | $37.4M | 4.7M | +10% |
| Nuveen, LLC | $34.7M | 4.4M | +50.4% |
| Rosalind Advisors, Inc. | $23M | 2.9M | -10% |
| Qube Research & Technologies Ltd | $22.9M | 2.9M | -29.7% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $20.8M | 2.6M | -1.5% |
| WELLINGTON MANAGEMENT GROUP LLP | $18.7M | 2.4M | +8.9% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.